arrow
R

Ryan E. Wiegand

Centers for Disease Control and Prevention
H指数:51
被引数:7,270

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023-March 2024

相关性疫苗接种行为对老年人COVID-19疫苗有效性估计的影响——VISION网络,2023年10月至2024年3月

Vaccine
IF3.5
2026-07-010
PRE
Effectiveness of Bivalent mRNA COVID-19 Vaccine Among Adults With Kidney Failure Receiving Dialysis: A Cohort Study From the Centers for Medicare and Medicaid Services

双价mRNA COVID-19疫苗在肾功能衰竭并接受透析的成人中的有效性:一项来自Centers for Medicare and Medicaid Services的队列研究

2025-09-190
PRE
Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged ≥18 years with end stage kidney disease - United States, September 2023-April 2024

2023-2024年COVID-19疫苗对≥18岁终末期肾病成人COVID-19相关住院的有效性 - 美国,2023年9月至2024年4月

VACCINE
IF3.5
2025-05-010
PRE
Using Multiple Methods to Estimate Respiratory Syncytial Virus (RSV)-associated Hospitalization Rates in Children Aged < 5 Years-Hamilton County, Ohio, 2009-2017

采用多种方法估算2009-2017年俄亥俄州汉密尔顿县<5岁儿童呼吸道合胞病毒(RSV)相关住院率

2025-04-160
OAAI
Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States

mRNA新型冠状病毒肺炎疫苗和杂交免疫预防美国成人SARS-CoV-2感染和症状新型冠状病毒肺炎的有效性

2025-01-080
PRE
Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers

信使RNA冠状病毒疾病2019 (新型冠状病毒肺炎) 疫苗接种与新型冠状病毒冠状病毒2感染后COVID后病情减少的关联

2024-11-130
OA
Innate immune activation restricts priming and protective efficacy of the radiation attenuated PfSPZ malaria vaccine-
2024-04-302
OA
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
2024-02-065
OA
Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023

流感疫苗对美国成年人甲型流感相关急诊科,紧急护理和住院治疗的有效性,2022-2023

2023-12-027
OA
Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022
2023-09-086
OA
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions-VISION Network, September 2022-April 2023
2023-07-016
PRE
Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods
2023-04-139
OA
Relative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Period-United States, 1 January 2022 to 31 March 2022
2023-02-0811
OA